Lupin announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its Chhatrapati Sambhajinagar (Aurangabad) facility, following a product-specific Pre-Approval Inspection from September 1 to September 5, 2025.

Speaking in this regard, Nilesh Gupta, Managing Director (MD), Lupin, said, “We are pleased to have received the EIR from the US FDA for our Aurangabad facility. This underscores our commitment to upholding the highest standards of quality and compliance, and delivering trusted healthcare solutions to patients worldwide.”

The company enjoys a strong position in India and the US across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health.